←
sciqst174,385 posts
sciqst avatar

sciqst

@sciqst

It’s pronounced “Sci-Quest.” 😉 Precise references in medicine. sciqst.com ByronInsight AG, Zurich, Switzerland

◷ Joined August 2023▧ 1,373 Photos and videos
sciqst avatar
sciqst@sciqst·2h

What if healing bone no longer required harvesting bone? 🦴 A 2026 trial involving 183 patients found a PTH-based bone graft substitute non-inferior to autograft, with 83.6% union at 16 weeks in the high-dose group [1]. But the evidence gap remains. A 2026 review found only 15 eligible studies across 1,751 screened papers [2]. 🚀 For orthopedic innovators, the opportunity extends beyond biomaterials: fewer donor-site complications, better recovery and stronger clinical evidence. The priority? Prove long-term outcomes, safety and cost-effectiveness before scaling adoption. 🤔 Should synthetic bone grafts become the new standard, or is clinical evidence still too limited? Sources: [1] [ncbi.nlm.nih.gov/pubmed/4153…](ncbi.nlm.nih.gov/pubmed/4153…) [2] [ncbi.nlm.nih.gov/pubmed/4210…](ncbi.nlm.nih.gov/pubmed/4210…) [3] [ncbi.nlm.nih.gov/pubmed/4258…](ncbi.nlm.nih.gov/pubmed/4258…) #Orthopedics #BoneGrafts #Biomaterials #MedTech

sciqst avatar
sciqst@sciqst·5h

What if the socket is no longer needed? 🦿 Osseointegration anchors prosthetic limbs directly to bone, transforming mobility. A 2026 study reported 93% implant survival at 5 years, alongside improved walking performance. But 40.3% required revision surgery [1]. ⚕️ A 2025 study also found promising upper-limb outcomes [2]. Yet infection risks and limited long-term evidence remain major barriers [3]. The opportunity goes beyond engineering: better rehabilitation, specialist training, and equitable access. Healthcare leaders must balance innovation with safety, cost, and patient outcomes. 🤔 Should osseointegration become a mainstream prosthetic option, or should unresolved risks keep it limited to specialist centres? [1] [ncbi.nlm.nih.gov/pubmed/4149…](ncbi.nlm.nih.gov/pubmed/4149…) [2] [ncbi.nlm.nih.gov/pubmed/3998…](ncbi.nlm.nih.gov/pubmed/3998…) [3] [ncbi.nlm.nih.gov/pubmed/4007…](ncbi.nlm.nih.gov/pubmed/4007…) #Osseointegration #Prosthetics #MedTech #Rehabilitation

sciqst avatar
sciqst@sciqst·8h

Removing the meniscus may relieve pain. But at what cost? 🦵 A 2026 study of 36,386 patients found osteoarthritis treatment was more common after meniscectomy than repair: 9.2% vs 6.7% within 2 years [1]. Yet preservation has trade-offs. A 2025 study reported a 32.7% reoperation risk within 5 years after repair [2]. 🔬 Modern techniques root repair, all-inside suturing and biological augmentation aim to protect native tissue. The 2025 EU-US consensus recommends tailored rehabilitation, often lasting 4 9 months after repair [3]. The priority? Preserve tissue when feasible, select patients carefully and measure long-term outcomes. 🤔 Where should surgeons draw the line between preserving tissue and ensuring durable results? [1] [pubmed.ncbi.nlm.nih.gov/4225…](pubmed.ncbi.nlm.nih.gov/4225…) [2] [pubmed.ncbi.nlm.nih.gov/4114…](pubmed.ncbi.nlm.nih.gov/4114…) [3] [pubmed.ncbi.nlm.nih.gov/4035…](pubmed.ncbi.nlm.nih.gov/4035…) #MeniscusRepair #KneePreservation #Orthopaedics #SportsMedicine

sciqst avatar
sciqst@sciqst·11h

What if the future of ACL surgery isn't reconstruction? 🦵 ACL treatment is entering a new era. In 2025, the FDA cleared an expanded indication for the BEAR implant, supporting ligament preservation rather than replacement [1]. A 2026 analysis of 11 randomized trials found no significant outcome differences among quadriceps, hamstring and patellar tendon grafts [2]. Meanwhile, biological ACL repair is gaining momentum, with promising functional outcomes [3]. 🔬 The opportunity? Better patient selection, smarter rehabilitation and innovation measured by long-term recovery not surgical novelty. 🤔 Should ACL innovation prioritize preserving native tissue or perfecting proven reconstruction techniques? [1] [accessdata.fda.gov/cdrhdocs/…](accessdata.fda.gov/cdrhdocs/…) [2] [ncbi.nlm.nih.gov/pmc/article…](ncbi.nlm.nih.gov/pmc/article…) [3] [ncbi.nlm.nih.gov/pmc/article…](ncbi.nlm.nih.gov/pmc/article…) #ACLReconstruction #SportsMedicine #Orthopedics #RegenerativeMedicine

sciqst avatar
sciqst@sciqst·14h

Shoulder replacement is entering a new era. 🚀 In 2024, reverse shoulder arthroplasty accounted for 70.4% of UK shoulder replacements [1]. A major shift in surgical practice. 🦾 Advances in 3D planning, augmented reality and navigation are improving implant positioning accuracy [2]. But precision isn't everything. A 2026 review highlights a critical gap: evidence of better long-term outcomes remains limited [3]. For hospitals and medtech leaders, the priority is clear: prove clinical value before scaling expensive technology. 🤔 Should innovation in shoulder arthroplasty be judged by surgical precision or long-term patient outcomes? Sources: [1] [ncbi.nlm.nih.gov/books/NBK61…](ncbi.nlm.nih.gov/books/NBK61…) [2] [ncbi.nlm.nih.gov/pubmed/3903…](ncbi.nlm.nih.gov/pubmed/3903…) [3] [ncbi.nlm.nih.gov/pubmed/4233…](ncbi.nlm.nih.gov/pubmed/4233…) #ShoulderArthroplasty #Orthopedics #MedTech #SurgicalInnovation

sciqst avatar
sciqst@sciqst·17h

The biggest risk in joint replacement isn't always in the operating room. 🦠 A 2026 study of 1.66 million arthroplasties found 1-year infection rates of 1.19% for knees and 1.28% for hips [1]. 💰 In Europe, a 2026 analysis estimated 22,794 annual infections and €123.6 million in re-revision costs [2]. Prevention is clinical and economic strategy. A 2025 study linked structured infection prevention to a 5.6% → 1.1% drop in surgical-site infections across orthopedic procedures [3]. The priority? Screening, targeted decolonization, antibiotic stewardship and consistent protocols. 🤔 Where should hospitals invest first to prevent PJI and which widely used practices deserve more scrutiny? [1] [ncbi.nlm.nih.gov/pubmed/4208…](ncbi.nlm.nih.gov/pubmed/4208…) [2] [ncbi.nlm.nih.gov/pubmed/4267…](ncbi.nlm.nih.gov/pubmed/4267…) [3] [ncbi.nlm.nih.gov/pubmed/4100…](ncbi.nlm.nih.gov/pubmed/4100…) #PJI #InfectionPrevention #Arthroplasty #PatientSafety

sciqst avatar
sciqst@sciqst·20h

Better tendon healing or just better MRI scans? A 2026 meta-analysis of 20 trials (1,327 shoulders) found biologic augmentation cut rotator cuff retear rates from 26.7% to 14.8%. Yet patients saw no clinically meaningful functional gains. [1] 🔬 The gap matters. The AAOS 2025 guideline does not support routine PRP for rotator cuff tendinopathy or partial tears. [2] A 2026 review of 355 patients found no significant PRP benefit over placebo for tennis elbow. [3] 💡 For clinics and investors, the benchmark must be lasting function not biological promise alone. 🤔 Where should the bar for adoption sit when tissue heals better but patients don't feel better? [1] [ncbi.nlm.nih.gov/pubmed/4275…](ncbi.nlm.nih.gov/pubmed/4275…) [2] [aaos.org/quality/quality-pro…](aaos.org/quality/quality-pro…) [3] [ncbi.nlm.nih.gov/pubmed/4150…](ncbi.nlm.nih.gov/pubmed/4150…) #Orthobiologics #TendonHealing #PRP #SportsMedicine Add the missing industry contextMake the practical takeaway more actionable

sciqst avatar
sciqst@sciqst·23h

A pelvic fracture can kill before surgery begins. 🚨 A 2026 multicentre study involving 948 patients highlights a critical challenge: controlling haemorrhage before irreversible shock develops. [1] Recent Australian data reported 7.2% in-hospital mortality among patients with haemodynamically unstable pelvic fractures. [2] ⚕️ Management demands rapid pelvic stabilisation, balanced resuscitation and timely haemorrhage control. Angioembolisation and preperitoneal packing are complementary strategies, selected according to physiology and resources. [3] The priority? Coordinated trauma pathways, not isolated interventions. 🤔 Should trauma centres prioritise immediate embolisation or faster surgical packing and how should limited resources influence that choice? Sources: [1] [ncbi.nlm.nih.gov/pubmed/4153…](ncbi.nlm.nih.gov/pubmed/4153…) [2] [ncbi.nlm.nih.gov/pubmed/4263…](ncbi.nlm.nih.gov/pubmed/4263…) [3] [ncbi.nlm.nih.gov/pubmed/4017…](ncbi.nlm.nih.gov/pubmed/4017…) #PelvicTrauma #TraumaSurgery #Orthopaedics

sciqst avatar
sciqst@sciqst·Nov 17

The next surgical breakthrough might be printed. 🦴 3D-printed orthopedic guides are turning patient scans into precise surgical tools. A 2025 study found 22% less time per screw placement in complex cervical spine surgery, with 98.7% placement accuracy [1]. A broader review found promising gains in surgical efficiency and fracture reduction [2]. 📊 But adoption still faces challenges: preparation time, costs, and anatomical complexity [3]. For hospitals, the opportunity is clear: validate outcomes, streamline production, and make personalized surgery scalable. 🤔 Should 3D-printed guides become standard practice, or should their use remain limited to complex cases? Sources: [1] [frontiersin.org/journals/sur…](frontiersin.org/journals/sur…) [2] [frontiersin.org/journals/med…](frontiersin.org/journals/med…) [3] [mdpi.com/1648-9144/62/3/599](mdpi.com/1648-9144/62/3/599?…) #3DPrinting #Orthopedics #SurgicalInnovation #MedTech

sciqst avatar
sciqst@sciqst·Nov 17

Smaller incisions. Better fracture care? 🦴 In 2026, osteoporosis-related fractures affect people over 55 at a staggering rate: 70 every minute worldwide [1]. A 2026 meta-analysis of 530 patients found infection rates of 3.4% with minimally invasive plating versus 9.1% with open fixation [2]. 📊 Yet a 2025 randomized trial found no clear superiority for minimally invasive fixation in tibial pilon fractures [3]. The takeaway? Smaller incisions are promising, but fracture stability, surgical expertise and patient selection remain critical. Healthcare leaders must invest in evidence-based training, not technology alone. 🤔 Should minimally invasive fixation become the default, or are we prioritizing smaller scars over proven outcomes? Sources: [1] [osteoporosis.foundation/news…](osteoporosis.foundation/news…) [2] [ncbi.nlm.nih.gov/research/bi…](ncbi.nlm.nih.gov/research/bi…) [3] [ncbi.nlm.nih.gov/pubmed/4054…](ncbi.nlm.nih.gov/pubmed/4054…) #FractureFixation #Orthopaedics #MinimallyInvasiveSurgery

sciqst avatar
sciqst@sciqst·Nov 17

The next fracture is often preventable. Yet we keep missing it. 🦴 In 2025, the International Osteoporosis Foundation reported 37 million fragility fractures annually and up to 80% of patients remain undiagnosed or untreated after a fracture. [1] 🚨 A 2026 Swiss study found 88% of hip fracture patients received no osteoporosis treatment within six months. [2] The opportunity? Prevention, not just repair. A 2025 study involving 100,198 people linked coordinated fracture care to fewer repeat fractures and lower mortality. [3] Healthcare leaders must prioritize screening, timely treatment and fracture liaison services. 🤔 Why do health systems invest so heavily in fracture treatment while leaving prevention underfunded? Sources: [1] [osteoporosis.foundation/news…](osteoporosis.foundation/news…) [2] [ncbi.nlm.nih.gov/pubmed/4152…](ncbi.nlm.nih.gov/pubmed/4152…) [3] [ncbi.nlm.nih.gov/pmc/article…](ncbi.nlm.nih.gov/pmc/article…) #Osteoporosis #FracturePrevention #BoneHealth #HealthyAgeing

sciqst avatar
sciqst@sciqst·Nov 17

What if damaged cartilage could repair itself? 🧬 Cartilage regeneration is moving beyond theory. A 2025 Phase III study of 100 patients found that hydrogel-based cell implantation improved knee function scores from 39.8 to 84.7 over five years [1]. Yet challenges remain. A 2026 review found promising results for stem cell hydrogel therapies, but evidence quality remains low [2]. With 528 million people affected by osteoarthritis globally, the clinical and economic stakes are enormous [3]. 🔬 The priority? Scalable therapies, rigorous trials and long-term durability not just impressive early results. 🤔 Should regenerative medicine prioritize biological breakthroughs or affordable treatments that reach more patients? [1] [ncbi.nlm.nih.gov/pmc/article…](ncbi.nlm.nih.gov/pmc/article…) [2] [ncbi.nlm.nih.gov/pmc/article…](ncbi.nlm.nih.gov/pmc/article…) [3] [who.int/news-room/fact-sheet…](who.int/news-room/fact-sheet…) #CartilageRegeneration #TissueEngineering #RegenerativeMedicine #Orthopedics

sciqst avatar
sciqst@sciqst·Nov 17

Better tendon healing. But better outcomes? 🧬 A 2026 meta-analysis of 20 trials (1,327 shoulders) found biologic augmentation reduced rotator cuff retear rates from 26.7% to 14.8%. Yet patient-reported benefits remained clinically modest [1]. Another 2026 review reported 35% lower retear risk with graft augmentation [2]. The 2025 AAOS guidelines support bioinductive implants but remain cautious about PRP [3]. 🔬 The opportunity is clear: stronger repairs. The challenge? Proving long-term functional value and cost-effectiveness. 🤔 Should biologic augmentation become standard practice, or remain reserved for high-risk tears until functional benefits are proven? [1] [ncbi.nlm.nih.gov/pubmed/4275…](ncbi.nlm.nih.gov/pubmed/4275…) [2] [ncbi.nlm.nih.gov/pubmed/4154…](ncbi.nlm.nih.gov/pubmed/4154…) [3] [aaos.org/rccpg2025](aaos.org/rccpg2025?utmsource…) #RotatorCuff #Biologics #ShoulderSurgery #Orthopedics

sciqst avatar
sciqst@sciqst·Nov 17

What if the best hip implant isn’t mass-produced? 🦴 In November 2026, the AAOS registry reached 5.2 million hip and knee procedures [1]. Meanwhile, a UK study of 52 patients reported zero custom acetabular component revisions at a median 51-month follow-up [2]. The shift is significant. 🛠️ Patient-specific, 3D-printed implants offer new options for complex hip reconstruction. But challenges remain. A 2026 study of 154 patients found 78% implant survival at five years [3]. For hospitals and manufacturers, the priority is clear: prove clinical value, improve affordability and scale responsibly. 🤔 Should personalized implants become mainstream, or remain reserved for complex cases? Sources: [1] [aaos.org/registries/publicat…](aaos.org/registries/publicat…) [2] [ncbi.nlm.nih.gov/pubmed/4290…](ncbi.nlm.nih.gov/pubmed/4290…) [3] [ncbi.nlm.nih.gov/pubmed/4268…](ncbi.nlm.nih.gov/pubmed/4268…) #HipImplants #3DPrinting #Orthopedics #MedTech

sciqst avatar
sciqst@sciqst·Nov 17

🤖 More precision. But better knees? Robotic-assisted knee replacement is gaining momentum. Yet 2026 evidence challenges the hype. A study of 697,145 knee replacements found nearly identical 5-year implant survival: 98.6% robotic vs. 98.5% conventional [1]. A randomized trial of 339 patients found no meaningful benefit at 12 months despite higher costs [2]. ⚕️ The challenge? Precision alone doesn't guarantee better outcomes. Hospitals must balance innovation, affordability and patient value. 📊 🤔 Should hospitals prioritize robotic technology or demand stronger evidence of long-term benefits before investing? [1] [bmj.com/content/394/bmj-2026…](bmj.com/content/394/bmj-2026…) [2] [sciencedirect.com/science/ar…](sciencedirect.com/science/ar…) [3] [ncbi.nlm.nih.gov/pubmed/4193…](ncbi.nlm.nih.gov/pubmed/4193…) #RoboticSurgery #KneeReplacement #Orthopedics #HealthTech

sciqst avatar
sciqst@sciqst·Nov 16

The future of diagnostics may be disposable. 🧬 In June 2026, the FDA cleared the first over-the-counter glucose biosensor for children aged 2+ [1]. Meanwhile, WHO reports that over half the world's population lacks basic diagnostic access [2]. Disposable biosensor platforms could change that. ⚡ Low-cost, single-use sensors offer faster testing, decentralized care and scalable monitoring. Yet diagnostics influence 70% of healthcare decisions while receiving just 3 5% of healthcare budgets [3]. The challenge? Scaling accuracy, affordability and sustainability together. 🤔 Should healthcare prioritize disposable diagnostics for wider access, or reusable platforms to reduce waste? [1] [fda.gov/news-events/press-an…](fda.gov/news-events/press-an…) [2] [who.int/news/item/25-05-2026…](who.int/news/item/25-05-2026…) [3] [who.int/health-topics/diagno…](who.int/health-topics/diagno…) #Biosensors #MedTech #Diagnostics